Zydus Pharmaceuticals, a US subsidiary of Indian drugmaker Cadila Healthcare, has reached an out of court agreement with Kowa Pharmaceuticals and Nissan Chemical, bringing to an end their ongoing patent infringement dispute.
Zydus and Cadila settled with Upsher-Smith Laboratories last week in a separate patent case related to the latter’s Qudexy XR (topiramate) extended-release capsules.
The present settlement will see Zydus marketing their generic version of cardiovascular therapy Livalo (pitavastatin calcium) under license from May 2, 2023, or before if certain conditions are met. Financial details were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze